[
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) Stock Moves -0.4%: What You Should Know",
    "summary": "Boston Scientific (BSX) closed the most recent trading day at $89.32, moving -0.4% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=1297caf2dfdcea6d1372943285b77adae9ddab3366e76ed321af464c7ef240ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735686019,
      "headline": "Boston Scientific (BSX) Stock Moves -0.4%: What You Should Know",
      "id": 132223260,
      "image": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) closed the most recent trading day at $89.32, moving -0.4% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=1297caf2dfdcea6d1372943285b77adae9ddab3366e76ed321af464c7ef240ee"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific price target raised to $101 from $97 at BTIG",
    "summary": "BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology names. BTIG is now modeling about $1.5B in U.S. Farapulse revenue in 2025, up from $1B in its prior projections, which had “conservatively” used its Q4 estimate as a runrate, the analyst tells investors in a research note, adding that BTIG believes that this new foreca",
    "url": "https://finnhub.io/api/news?id=c9f8bf1e9a70eb751f58939951ba8371a0f2902878daed3879497155b1c78474",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735646707,
      "headline": "Boston Scientific price target raised to $101 from $97 at BTIG",
      "id": 132215545,
      "image": "",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology names. BTIG is now modeling about $1.5B in U.S. Farapulse revenue in 2025, up from $1B in its prior projections, which had “conservatively” used its Q4 estimate as a runrate, the analyst tells investors in a research note, adding that BTIG believes that this new foreca",
      "url": "https://finnhub.io/api/news?id=c9f8bf1e9a70eb751f58939951ba8371a0f2902878daed3879497155b1c78474"
    }
  },
  {
    "ts": null,
    "headline": "Should You Hold Quest Diagnostics Stock in Your Portfolio Now?",
    "summary": "DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.",
    "url": "https://finnhub.io/api/news?id=9eead7117dd75f7a14c44c1a8d75426ff30d063d644e50e557189a7a309be4aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735646280,
      "headline": "Should You Hold Quest Diagnostics Stock in Your Portfolio Now?",
      "id": 132215133,
      "image": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.",
      "url": "https://finnhub.io/api/news?id=9eead7117dd75f7a14c44c1a8d75426ff30d063d644e50e557189a7a309be4aa"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corporation: Solid Financials And Upward Continuation",
    "summary": "Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. Check out why I rate BSX stock a buy now.",
    "url": "https://finnhub.io/api/news?id=a4e22909fa64ee025c21858cdd30125a56f5a72b310a82031808f6800d4613e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735635311,
      "headline": "Boston Scientific Corporation: Solid Financials And Upward Continuation",
      "id": 132214048,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. Check out why I rate BSX stock a buy now.",
      "url": "https://finnhub.io/api/news?id=a4e22909fa64ee025c21858cdd30125a56f5a72b310a82031808f6800d4613e2"
    }
  }
]